ZYME

Company Overview — What Does Zymeworks Inc. Do?

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Zymeworks Inc. (ZYME) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Kenneth H. Galbraith and employs approximately 460 people. With a market capitalization of $1.9B, ZYME is one of the notable companies in the Healthcare sector.

Zymeworks Inc. (ZYME) Stock Rating — Hold (April 2026)

As of April 2026, Zymeworks Inc. receives a Hold rating with a composite score of 37.1/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ZYME ranks #1,703 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Zymeworks Inc. ranks #163 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ZYME Stock Price and 52-Week Range

Zymeworks Inc. (ZYME) currently trades at $26.32. The stock lost $1.03 (3.8%) in the most recent trading session. The 52-week high for ZYME is $28.49, which means the stock is currently trading -7.6% from its annual peak. The 52-week low is $9.03, putting the stock 191.5% above its annual trough. Recent trading volume was 533K shares, suggesting relatively thin trading activity.

Is ZYME Overvalued or Undervalued? — Valuation Analysis

Zymeworks Inc. (ZYME) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 7.20x, versus the sector average of 2.75x. The price-to-sales ratio is 16.17x, compared to 1.66x for the average Healthcare stock.

At current multiples, Zymeworks Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Zymeworks Inc. Profitability — ROE, Margins, and Quality Score

Zymeworks Inc. (ZYME) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -26.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -20.1% versus the sector average of -33.1%.

On a margin basis, Zymeworks Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -97.4% (sector: -66.1%). Net profit margin stands at -84.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 43.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ZYME Debt, Balance Sheet, and Financial Health

Zymeworks Inc. has a debt-to-equity ratio of 29.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.88x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $65M.

ZYME has a beta of 0.72, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Zymeworks Inc. is 55/100, reflecting average volatility within the normal range for its sector.

Zymeworks Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Zymeworks Inc. reported revenue of $119M and earnings per share (EPS) of $-1.08. Net income for the quarter was $-70M. Gross margin was 100.0%. Operating income came in at $-83M.

In FY 2025, Zymeworks Inc. reported revenue of $106M and earnings per share (EPS) of $-1.08. Net income for the quarter was $-81M. Revenue grew 38.9% year-over-year compared to FY 2024. Operating income came in at $-93M.

In Q3 2025, Zymeworks Inc. reported revenue of $28M and earnings per share (EPS) of $-0.26. Net income for the quarter was $-20M. Revenue grew 72.6% year-over-year compared to Q3 2024. Operating income came in at $-22M.

In Q2 2025, Zymeworks Inc. reported revenue of $49M and earnings per share (EPS) of $0.03. Net income for the quarter was $2M. Revenue grew 153.2% year-over-year compared to Q2 2024. Operating income came in at $-674,000.

Over the past 8 quarters, Zymeworks Inc. has demonstrated a growth trajectory, with revenue expanding from $19M to $119M. Investors analyzing ZYME stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ZYME Dividend Yield and Income Analysis

Zymeworks Inc. (ZYME) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ZYME Momentum and Technical Analysis Profile

Zymeworks Inc. (ZYME) has a momentum factor score of 65/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 15/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ZYME vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Zymeworks Inc. (ZYME) ranks #163 out of 838 stocks based on the Blank Capital composite score. This places ZYME in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ZYME against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ZYME vs S&P 500 (SPY) comparison to assess how Zymeworks Inc. stacks up against the broader market across all factor dimensions.

ZYME Next Earnings Date

No upcoming earnings date has been announced for Zymeworks Inc. (ZYME) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ZYME? — Investment Thesis Summary

Zymeworks Inc. presents a balanced picture with arguments on both sides. The quality score of 25/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. Price momentum is positive at 65/100, suggesting the trend favors buyers.

In summary, Zymeworks Inc. (ZYME) earns a Hold rating with a composite score of 37.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ZYME stock.

Related Resources for ZYME Investors

Explore more research and tools: ZYME vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ZYME head-to-head with peers: ZYME vs AZN, ZYME vs SLGL, ZYME vs VMD.